Lv4
482 积分 2025-09-28 加入
中国变应性鼻炎诊断和治疗指南
18天前
已完结
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
1个月前
已完结
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
1个月前
已完结
Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial
2个月前
已关闭
Abstract CT003: Initial results of a phase 1 study of AMG 355, a novel anti-CCR8 antibody as a single agent and in combination with pembrolizumab in patients with solid tumors
2个月前
已完结
Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies
2个月前
已关闭
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies
2个月前
已完结
皖公网安备34019202002308
